Skip to main content
. 2017 Sep 18;8(50):87607–87622. doi: 10.18632/oncotarget.20999

Figure 6. The impact of AraC treatment on hematopoietic cells expressing AML1-ETO9a.

Figure 6

(A), (B), and (C) WT and Necdin null hematopoietic cells expressing AML1-ETO9a were treated with DMSO or different concentrations of chemotherapy drug cytarabine (AraC). 24 (A), 48 (B), and 72 (C) hours after AraC treatment, the viability of treated hematopoietic cells was measured by cell counting (n=3). (D) and (E) WT and Necdin null hematopoietic cells expressing AML1-ETO9a were treated with DMSO or different concentrations of AraC. 48 hours after AraC treatment, the frequency of early apoptotic cells (Annexin V+PI−) and late apoptotic cells (Annexin V+PI+) was determined by flow cytometry analysis (*p<0.05, **p<0.01, ***p<0.001, n=3). (F) and (G) WT and Necdin null hematopoietic cells expressing AML1-ETO9a were treated with DMSO or different concentrations of AraC. 72 hours after AraC treatment, the frequency of early apoptotic cells (Annexin V+PI−) and late apoptotic cells (Annexin V+PI+) was determined by flow cytometry analysis (*p<0.05, n=3).